While previous studies show albumin provides anti-inflammatory properties of cirrhosis patients, there is a scarcity of larger clinical trials. Whether targeting a serum albumin level of 30 g…
[mc4wp_form id="449"]
Increased risk for Clostridium difficile (C diff) infection remained elevated for up to a year after the conclusion of treatment with proton-pump inhibitors (PPIs), according to a paper…
Early phase data shows higher rates of ulcerative colitis will achieve clinical remission and improvements treated with ABX464 when compared to placebo. A team, led by Severine Vermeire,…
Using elevated white blood cell count alone as a predictor for Clostridium difficile (C diff) infection nucleic acid testing (NAAT) positivity is not sensitive enough and has low…
While liver transplantation from donors who died from circulatory disease is often linked to an increased risk of nonanastomotic biliary strictures, hypothermic oxygenated machine perfusion of livers could…
Proton pump inhibitor (PPI) use does not lead to bacterial overgrowth in the small intestine, according to a paper published in Digestive Diseases and Sciences. Investigators from Cedars-Sinai…
New data shows upadacitinib increases rates of clinical remission when compared to placebo in patients with ulcerative colitis. AbbVie announced the results from the trial testing 45 mg,…
Linaclotide has been marketed as LINZESS to treat irritable bowel syndrome with constipation. The US Food and Drug Administration (FDA) has approved the first generic drug to treat…
Proton pump inhibitors (PPIs), a common therapy for pediatric acid-related gastrointestinal tract disorders, may be linked to increased risk of asthma development in children. A new cohort study…
Metabolomics, the analysis of metabolites in a biological specimen, could be a tool to identify intestinal alterations commonly found in inflammatory bowel disease (IDB) and could be further…